908 Devices Inc.MASS

NasdaqHealthcareLaboratory Analytical Instruments
Price (close)
$11.52
Market cap
$476.2M
P/E
—
Revenue (TTM)
$60.8M
Net income
-$34.7M
Dividend yield
—
1-year total return
40.1%
Net margin
-57.0%
Revenue growth
13.4%
Debt / equity
—

What 908 Devices Inc. does.

We are making chemical analysis simple, smart and speedy with our purpose-built handheld devices that empower people to take swift action in life-altering applications.

We have developed an innovative suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, or Mass Spec, and optical spectroscopy, analytics and machine learning technologies, we make devices that are significantly smaller and more accessible than conventional laboratory instruments. Our devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The term “products” or “devices” used in this “Business” section each refer to the MX908, ThreatID, ProtectIR, XplorIR, and VipIR.

We create simplified measurement devices that our customers can use as accurate tools where-and-when their work needs to be done, rather than overly complex and centralized analytical instrumentation. We believe the insights and answers our devices provide accelerate workflows, reduce costs, and offer transformational opportunities for our end users.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$26.9M$42.2M$46.9M$50.2M$47.7M$56.2M
Net income-$12.8M-$22.2M-$33.6M-$36.4M-$72.2M$19.5M
Free cash flow$4.1M-$29.8M-$23.0M-$27.1M-$30.8M-$24.6M

More on MASS.

Figures from 908 Devices Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.